Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069615 | 0.84 | HTR2C (0.44) | HTR2CBCHEACHES100A4 | |
| SCHEMBL7661693 | 0.83 | HTR2C (0.43) | HTR2CBCHEACHE | |
| SCHEMBL27707894 | 0.82 | HTR2C (0.46) | HTR2CHTR2AS100A4ADORA3AR | |
| SCHEMBL2390468 | 0.82 | HTR2C (0.46) | HTR2CHTR2AS100A4ADORA3AR | |
| SCHEMBL11078614 | 0.81 | BCHE (0.38) | HTR2CBCHEACHEHTR2ACYP19A1 | |
| SCHEMBL16377312 | 0.80 | S100A4 (0.55) | ACHES100A4LMNAMETAP1CYP19A1 | |
| SCHEMBL6588001 | 0.79 | MAOB (0.47) | HTR2CHTR2AHSD11B1CYP19A1 | |
| SCHEMBL7031699 | 0.79 | HTR2C (0.41) | HTR2CAKR1C3LMNA | |
| SCHEMBL19237102 | 0.78 | CDK8 (0.43) | HTR2CBCHEACHEHTR2ALMNA | |
| SCHEMBL23617909 | 0.78 | HTR2C (0.43) | HTR2CHTR2AS100A4ADORA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8815881-B2 | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2603496-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| CN-103068806-A | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds | SIENA BIOTECH SPA | 2013-04-24 | — | — | CN | disclosed |
| WO-2012019966-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) | 2012-02-09 | — | — | US | disclosed |
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | 4SC AG (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009149906-A2 | PREPARATION OF SILOXY-BRIDGED METALLOCENES | BASELL POLYOLEFINE GMBH (DE) | 2009-12-17 | — | — | WO | disclosed |
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | LEBAN JOHANN | 2009-07-09 | — | — | US | disclosed |
| US-7544825-B1 | Preparation of siloxy-bridged metallocenes | BASELL POLYOLEFINE GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | 4SC AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176716-A1 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | HTR2C 1861/4885BCHE 3818/4885ACHE 4749/4885 |
| US-20070037753-A1 | Inhibitors of cancer cell, T-cell and keratinocyte proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | HTR2C 1910/4885BCHE 3695/4885ACHE 4754/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | HTR2C 78/4885BCHE 682/4885ACHE 389/4885 |
| US-20140336208-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | HTR2C 808/4885BCHE 90/4885ACHE 331/4885 |
| US-20110263486-A1 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, EGFR, MKI67 | HTR2C 1802/4885BCHE 3907/4885ACHE 4752/4885 |
| US-20120035195-A1 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | HTR2C 808/4885BCHE 90/4885ACHE 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.